Petrov D.
131
Coauthors
14
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 3 |
| 2018 | 2 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Neurología | 13 |
| Neuropsicología | 7 |
| Medicamento | 4 |
| Inmunología | 1 |
| Biología | 1 |
| Biología molecular | 1 |
| Medicina interna | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 14 |
| Fisiología humana | 9 |
| Farmacología y terapéutica | 4 |
| Problemas sociales y servicios a grupos | 3 |
| Medicina y salud | 1 |
| Salud y seguridad personal | 1 |
| Ginecología, obstetricia, pediatría, geriatría | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 14 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Antoni Camins | 14 |
| Folch J. | 13 |
| Pedros I. | 11 |
| Zárate C.B. | 10 |
| Pallás M. | 9 |
| Auladell C. | 9 |
| Ettcheto M. | 8 |
| Abad S. | 7 |
| Olloquequi J. | 5 |
| De Lemos M.L. | 4 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Vulnerability of calbindin, calretinin and parvalbumin in a transgenic/knock-in APPswe/PS1dE9 mouse model of Alzheimer disease together with disruption of hippocampal neurogenesis
ArticleAbstract: The pathogenesis of Alzheimer disease (AD) is characterized by accumulation of β-amyloid protein inPalabras claves:Alzheimer disease, APPswe/PS1dE9 mouse, Calbindin, Calretinin, hippocampus, ParvalbuminAutores:Antoni Camins, Auladell C., Brox S., De Lemos M.L., Olloquequi J., Petrov D., Romero R., Verdaguer E.Fuentes:scopusReview of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein
OtherAbstract: Introduction Alzheimer disease (AD) is a major neurodegenerative disorder which eventually results iPalabras claves:Alzheimer disease, Amyloid hypotheses, Beta-amyloid, Beta-secretase, Gamma-secretaseAutores:Abad S., Antoni Camins, Ettcheto M., Folch J., Miguel Marin, Olloquequi J., Pedros I., Petrov D.Fuentes:scopusHypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice
ArticleAbstract: Previous studies suggest that Alzheimer's disease (AD) neurobiology could not be explained solely byPalabras claves:Alzheimer's disease, APP/PS1, cholesterol, hippocampus, LDLR-/-, OXPHOSAutores:Alegret M., Antoni Camins, De Lemos M.L., Ettcheto M., Folch J., Laguna J.C., Pallás M., Pedros I., Petrov D.Fuentes:scopusCurrent Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusAdipokine pathways are altered in hippocampus of an experimental mouse model of Alzheimer’s disease
ArticleAbstract: A growing body of evidence suggests that β-amyloid peptides (Aβ) are unlikely to be the only factorPalabras claves:ALZHÉIMER, APP/PS1, hippocampus, leptin, prolactinAutores:Abad S., Antoni Camins, Artiach G., Folch J., Pallás M., Pedros I., Petrov D., Ramon-Duaso C., Sureda F.X., Zárate C.B.Fuentes:scopus